[
  {
    "ts": null,
    "headline": "'Stablecoin Summer': Stripe Makes Tender Offer at $159 Billion Valuation",
    "summary": "Payments giant Stripe made a tender offer valuing the firm at $159 billion as payments and stablecoin volumes rise.",
    "url": "https://finnhub.io/api/news?id=59d9141dff57e2823013e3424719f526bd644aa9865f4ebc189cdec2d8283ef1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771968569,
      "headline": "'Stablecoin Summer': Stripe Makes Tender Offer at $159 Billion Valuation",
      "id": 139201666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Payments giant Stripe made a tender offer valuing the firm at $159 billion as payments and stablecoin volumes rise.",
      "url": "https://finnhub.io/api/news?id=59d9141dff57e2823013e3424719f526bd644aa9865f4ebc189cdec2d8283ef1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Secures $495 Million China Obesity Drug Deal",
    "summary": "Company gains exclusive mainland China rights to ecnoglutide, approved for diabetes and under obesity review.",
    "url": "https://finnhub.io/api/news?id=0b3a45ac5602845b9c65b0d46cda93f675c92d6f516ddb3f85af0913c2c7274e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771962359,
      "headline": "Pfizer Secures $495 Million China Obesity Drug Deal",
      "id": 139201667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Company gains exclusive mainland China rights to ecnoglutide, approved for diabetes and under obesity review.",
      "url": "https://finnhub.io/api/news?id=0b3a45ac5602845b9c65b0d46cda93f675c92d6f516ddb3f85af0913c2c7274e"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer",
    "summary": "NEW YORK, February 24, 2026--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).",
    "url": "https://finnhub.io/api/news?id=5be8aa4995c3016e7b1644c0587625c927fea562d71c22b3d9c8760f76c58d15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771961340,
      "headline": "U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer",
      "id": 139200986,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, February 24, 2026--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).",
      "url": "https://finnhub.io/api/news?id=5be8aa4995c3016e7b1644c0587625c927fea562d71c22b3d9c8760f76c58d15"
    }
  },
  {
    "ts": null,
    "headline": "Smart Money Is Betting Big In PFE Options",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=cf3f1ab99a82a2e4dc611ee20e4f8beb566d2c0073041da8f825ab290a02b3c4",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771948856,
      "headline": "Smart Money Is Betting Big In PFE Options",
      "id": 139208038,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=2048&height=1536",
      "related": "PFE",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=cf3f1ab99a82a2e4dc611ee20e4f8beb566d2c0073041da8f825ab290a02b3c4"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas Q4 Earnings Call Highlights",
    "summary": "Arvinas (NASDAQ:ARVN) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a strategy centered on advancing four Phase 1 clinical programs and preparing for multiple data disclosures in 2026, while also providing an update on the commercialization path for vepdege",
    "url": "https://finnhub.io/api/news?id=585883c0dc3dcbf71036e15d1346d0c9389e415417e85d441340e31e251b9d01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771947894,
      "headline": "Arvinas Q4 Earnings Call Highlights",
      "id": 139197433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Arvinas (NASDAQ:ARVN) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a strategy centered on advancing four Phase 1 clinical programs and preparing for multiple data disclosures in 2026, while also providing an update on the commercialization path for vepdege",
      "url": "https://finnhub.io/api/news?id=585883c0dc3dcbf71036e15d1346d0c9389e415417e85d441340e31e251b9d01"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $29.30 as of February 9th. Viking Therapeutics (VKTX) has emerged as a compelling scientific and strategic play in the obesity and metabolic therapy space, particularly following Novo Nordisk’s approval of the Wegovy® Pill, […]",
    "url": "https://finnhub.io/api/news?id=029b7dbdde0edbce7cc31f124b1535e3a85c362df061865139ed575048ff5a0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771946275,
      "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
      "id": 139197398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $29.30 as of February 9th. Viking Therapeutics (VKTX) has emerged as a compelling scientific and strategic play in the obesity and metabolic therapy space, particularly following Novo Nordisk’s approval of the Wegovy® Pill, […]",
      "url": "https://finnhub.io/api/news?id=029b7dbdde0edbce7cc31f124b1535e3a85c362df061865139ed575048ff5a0b"
    }
  },
  {
    "ts": null,
    "headline": "This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income",
    "summary": "Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.",
    "url": "https://finnhub.io/api/news?id=55ad30570de4db5fc604ca7d5a879020d45348e8aaa9b7183e75dff0d4477b52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771944600,
      "headline": "This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income",
      "id": 139197435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.",
      "url": "https://finnhub.io/api/news?id=55ad30570de4db5fc604ca7d5a879020d45348e8aaa9b7183e75dff0d4477b52"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Traditional Approval To Encorafenib For Metastatic Colorectal Cancer With A BRAF V600E Mutation",
    "summary": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation",
    "url": "https://finnhub.io/api/news?id=b5f40ace381eb6a6d9400e2071346b378e63949c2f953a1212374ddfe287ff19",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771941490,
      "headline": "FDA Grants Traditional Approval To Encorafenib For Metastatic Colorectal Cancer With A BRAF V600E Mutation",
      "id": 139208039,
      "image": "",
      "related": "PFE",
      "source": "Benzinga",
      "summary": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation",
      "url": "https://finnhub.io/api/news?id=b5f40ace381eb6a6d9400e2071346b378e63949c2f953a1212374ddfe287ff19"
    }
  },
  {
    "ts": null,
    "headline": "Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee",
    "summary": "In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (C",
    "url": "https://finnhub.io/api/news?id=6f9a8c145beb2ad32786b019b21939e2b27e845829a39cec3984f923fcc98d34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771937100,
      "headline": "Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee",
      "id": 139194516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (C",
      "url": "https://finnhub.io/api/news?id=6f9a8c145beb2ad32786b019b21939e2b27e845829a39cec3984f923fcc98d34"
    }
  },
  {
    "ts": null,
    "headline": "Anti Venom Market Competitive Landscape Report 2025: Top Companies Analysis, Profiles, Strategic Developments, Mergers, Sustainability Goals, Product Innovations and Launches, Revenues",
    "summary": "The global anti-venom market is poised for significant growth, projected to climb from US$ 1.25 billion in 2025 to US$ 2.07 billion by 2033, at a CAGR of 6.51%. This increase is driven by the rise in snakebite incidences, technological advancements in anti-venom production, and government efforts to improve accessibility. Key players like Bharat Serums and Vaccines Limited, Boehringer Ingelheim, and Pfizer Inc. are central to this market, contributing through innovations and expansions. Enhanced",
    "url": "https://finnhub.io/api/news?id=1f4ea1d998ef8caa1540a5d731ccc56d0a0323aa3317c478d145682ef9c95fe0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771936020,
      "headline": "Anti Venom Market Competitive Landscape Report 2025: Top Companies Analysis, Profiles, Strategic Developments, Mergers, Sustainability Goals, Product Innovations and Launches, Revenues",
      "id": 139194517,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global anti-venom market is poised for significant growth, projected to climb from US$ 1.25 billion in 2025 to US$ 2.07 billion by 2033, at a CAGR of 6.51%. This increase is driven by the rise in snakebite incidences, technological advancements in anti-venom production, and government efforts to improve accessibility. Key players like Bharat Serums and Vaccines Limited, Boehringer Ingelheim, and Pfizer Inc. are central to this market, contributing through innovations and expansions. Enhanced",
      "url": "https://finnhub.io/api/news?id=1f4ea1d998ef8caa1540a5d731ccc56d0a0323aa3317c478d145682ef9c95fe0"
    }
  },
  {
    "ts": null,
    "headline": "Celcuity Adds Oncology Veteran To Board As Gedatolisib Commercial Stakes Rise",
    "summary": "Celcuity (NasdaqCM:CELC) has appointed Charles (Chip) R. Romp to its Board of Directors. Romp brings extensive oncology commercialization experience from senior roles at Seagen and Genentech. The appointment comes as Celcuity advances Gedatolisib in collaboration with Pfizer. Celcuity, trading at $105.15, has seen very large share price gains over the past year, with a 1 year return above 800% and a 3 year return above 800% as well. Short term moves have been more mixed, with a 0.6% return...",
    "url": "https://finnhub.io/api/news?id=c6f73ec41c566d330ed215258b2c13e32ea7fada20cfe30bc93cf41752a8f5e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771931128,
      "headline": "Celcuity Adds Oncology Veteran To Board As Gedatolisib Commercial Stakes Rise",
      "id": 139193319,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Celcuity (NasdaqCM:CELC) has appointed Charles (Chip) R. Romp to its Board of Directors. Romp brings extensive oncology commercialization experience from senior roles at Seagen and Genentech. The appointment comes as Celcuity advances Gedatolisib in collaboration with Pfizer. Celcuity, trading at $105.15, has seen very large share price gains over the past year, with a 1 year return above 800% and a 3 year return above 800% as well. Short term moves have been more mixed, with a 0.6% return...",
      "url": "https://finnhub.io/api/news?id=c6f73ec41c566d330ed215258b2c13e32ea7fada20cfe30bc93cf41752a8f5e7"
    }
  },
  {
    "ts": null,
    "headline": "Novo to cut GLP-1 drug prices; Palvella soars on study data",
    "summary": "Wegovy and Ozempic’s list prices will be reduced by as much as 50% effective next year. Elsewhere, Palvella’s market value surged past $1 billion while Pfizer nabbed rights to another obesity drug.",
    "url": "https://finnhub.io/api/news?id=809dfbd826f8b6e00bab14e2d263b7165d82841dc4f963aaeea34c1e8ce2a00b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771930800,
      "headline": "Novo to cut GLP-1 drug prices; Palvella soars on study data",
      "id": 139198929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Wegovy and Ozempic’s list prices will be reduced by as much as 50% effective next year. Elsewhere, Palvella’s market value surged past $1 billion while Pfizer nabbed rights to another obesity drug.",
      "url": "https://finnhub.io/api/news?id=809dfbd826f8b6e00bab14e2d263b7165d82841dc4f963aaeea34c1e8ce2a00b"
    }
  },
  {
    "ts": null,
    "headline": "What's Going On With Kyntra Bio Stock Tuesday?",
    "summary": "Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.",
    "url": "https://finnhub.io/api/news?id=dece31c65759d68c9d26d6491553796b27d937de5cb66ddba03fa0c6fbac4d3a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771925228,
      "headline": "What's Going On With Kyntra Bio Stock Tuesday?",
      "id": 139194205,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/24/Genetic-Research-And-Biotech-Science-Con_0.jpeg?width=2048&height=1536",
      "related": "PFE",
      "source": "Benzinga",
      "summary": "Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.",
      "url": "https://finnhub.io/api/news?id=dece31c65759d68c9d26d6491553796b27d937de5cb66ddba03fa0c6fbac4d3a"
    }
  },
  {
    "ts": null,
    "headline": "Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China",
    "summary": "Hangzhou Sciwind Biosciences Co., Ltd. (\"Sciwind Biosciences\") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China. Sciwind Biosciences will remain the Marketing Authoriz",
    "url": "https://finnhub.io/api/news?id=8aed8372f55acc7c373a67d88506822fb81785b9fe52c59ceff6d30717b9f38e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771910520,
      "headline": "Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China",
      "id": 139190985,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Hangzhou Sciwind Biosciences Co., Ltd. (\"Sciwind Biosciences\") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China. Sciwind Biosciences will remain the Marketing Authoriz",
      "url": "https://finnhub.io/api/news?id=8aed8372f55acc7c373a67d88506822fb81785b9fe52c59ceff6d30717b9f38e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results",
    "summary": "Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical studies in weight management. The company also reported promising pivotal BREAKWATER trial results for BRAFTOVI in metastatic colorectal cancer. Together, these developments highlight fresh activity in Pfizer's pipeline across both metabolic disease and oncology. For investors watching NYSE:PFE, these moves come with the stock trading around $27.06 and mixed longer term...",
    "url": "https://finnhub.io/api/news?id=1970b826b0e56601a244e90c1bc9948149c9eb3ea812ce2ddbcad61b9b0757c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771909582,
      "headline": "Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results",
      "id": 139190986,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical studies in weight management. The company also reported promising pivotal BREAKWATER trial results for BRAFTOVI in metastatic colorectal cancer. Together, these developments highlight fresh activity in Pfizer's pipeline across both metabolic disease and oncology. For investors watching NYSE:PFE, these moves come with the stock trading around $27.06 and mixed longer term...",
      "url": "https://finnhub.io/api/news?id=1970b826b0e56601a244e90c1bc9948149c9eb3ea812ce2ddbcad61b9b0757c3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer China Secures Exclusive Mainland China Commercialization Rights For Ecnoglutide Injection In Deal Worth Up To $495M With Sciwind Biosciences",
    "summary": "Pfizer China Secures Exclusive Mainland China Commercialization Rights For Ecnoglutide Injection In Deal Worth Up To $495M With Sciwind Biosciences",
    "url": "https://finnhub.io/api/news?id=ecad31da5f689bea778435cc1c84dd59124bfa258a29cffe35c6288f89ceaa65",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771907697,
      "headline": "Pfizer China Secures Exclusive Mainland China Commercialization Rights For Ecnoglutide Injection In Deal Worth Up To $495M With Sciwind Biosciences",
      "id": 139195596,
      "image": "",
      "related": "PFE",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ecad31da5f689bea778435cc1c84dd59124bfa258a29cffe35c6288f89ceaa65"
    }
  },
  {
    "ts": null,
    "headline": "Russia's war on Ukraine puts women off having children — and that could spell economic disaster",
    "summary": "Four years of war have discouraged Ukrainian and Russian women from having children, and that could impact their economies in the future.",
    "url": "https://finnhub.io/api/news?id=53795300e06e0d4454e6b04b451c0e619690754126ab2762ed8dab8647314a9d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771895025,
      "headline": "Russia's war on Ukraine puts women off having children — and that could spell economic disaster ",
      "id": 139198069,
      "image": "https://image.cnbcfm.com/api/v1/image/108268945-1771917055711-gettyimages-1583281302-uk_20230807_ukr61.jpeg?v=1771917103&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Four years of war have discouraged Ukrainian and Russian women from having children, and that could impact their economies in the future.",
      "url": "https://finnhub.io/api/news?id=53795300e06e0d4454e6b04b451c0e619690754126ab2762ed8dab8647314a9d"
    }
  }
]